Peptide Serums: How to Choose and Use Them for Maximum Results

Key Takeaways

• Compounds covered: Palmitoyl pentapeptide (pal-KTTKS/Matrixyl), argireline (acetyl hexapeptide-3), GHK-Cu (topical and injectable), GEKG tetrapeptide, matrikine-derived peptides
• Goal area: Anti-aging skin appearance, wrinkle reduction, collagen support, skin texture
• Evidence range: Ranges from RCTs (pal-KTTKS at 3 ppm; single-site wrinkle-reduction trial for argireline) to ex vivo and in vitro data (GHK-Cu + HA synergy, matrikine peptides); no peptide serum category has large-scale Phase 3-equivalent trial data
• Regulatory range: All topical cosmetic peptide serums regulated as cosmetic ingredients under FDA cosmetics law; injectable GHK-Cu is not an FDA-approved drug — no formulation of GHK-Cu has been evaluated or approved by the FDA for any therapeutic indication
• Key biomarkers for injectable peptide use: IGF-1, comprehensive metabolic panel, CBC, hs-CRP
• As of April 2026: Topical cosmetic peptide ingredients are regulated under FDA cosmetics law (including MoCRA 2022), which is a regulatory framework separate from the FDA bulk drug substance actions announced through 2026 concerning certain injectable compounded peptides. Cosmetic-ingredient regulatory status can change; check product labels and FDA cosmetic-ingredient guidance for current status.
• Bottom line: Pal-KTTKS and argireline have the strongest ingredient-level RCT evidence for serum applications; formulation quality, concentration disclosure, and stability data are more predictive of real-world efficacy than ingredient name alone.

Understanding the Biology of Peptide Serum Action

A peptide serum is only as effective as its ability to deliver intact, bioactive peptide to the dermis — the connective tissue layer 1 to 2 mm below the skin surface where fibroblasts, collagen fibrils, and elastin fibers reside. The stratum corneum, the outermost layer of the epidermis, is a barrier of corneocytes embedded in a lipid matrix that evolved to exclude large molecules, microorganisms, and water loss. Most peptides face that barrier as an obstacle.

Gorouhi and Maibach, in their 2009 foundational review in the International Journal of Cosmetic Science, established that stability and penetration barriers to reach the dermis and interact with fibroblasts. Two principal mechanisms reduce a peptide's effectiveness before it reaches the dermis: degradation by proteases in the product formulation or on the skin surface, and physical barrier exclusion by the stratum corneum lipid matrix. Formulation chemistry — the vehicle, pH, preservatives, co-ingredients, and molecular modifications to the peptide itself — determines how much of the applied dose arrives at the target tissue intact.

The aging biology that peptide serums target is the same collagen-loss mechanism that drives skin aging more broadly. Cole, Quan, and Voorhees' 2018 review in the Journal of Cell Communication and Signaling established that fibroblast–ECM failure in skin aging is central: collagen fragmentation reduces fibroblast mechanical tension, which reduces collagen synthesis and increases MMP-driven matrix degradation in a self-reinforcing cycle. Signal peptides attempt to restore the collagen-synthesis signal; carrier peptides deliver required mineral cofactors; neurotransmitter-inhibitor peptides are proposed to act at the neuromuscular junction to reduce expression-line formation. A serum's efficacy depends on delivering the right class of peptide to the right tissue at a bioactive concentration. These mechanistic descriptions reflect the published in vitro and preclinical literature on cosmetic peptide ingredients. They are not FDA-evaluated efficacy endpoints, and topical cosmetic peptides are not evaluated or approved by the FDA to affect skin structure or function in the way approved drugs are.

Peptide Serum Ingredients: A Quick Comparison

The following peptide ingredients appear in commercially available serums with published evidence. Ordered by strength of clinical evidence for the specific ingredient in a serum or topical formulation context.

• Compound: Palmitoyl pentapeptide-4 (pal-KTTKS / Matrixyl)
  Mechanism for serums: Signal peptide — mimics collagen-derived matrikine fragment; stimulates fibroblast collagen I, III, and fibronectin synthesis
  Evidence: 12-week double-blind split-face RCT at 3 ppm — significant wrinkle/fine line reduction
  FDA status: Cosmetic ingredient; not evaluated or approved as a drug
  SP availability: Available as topical cosmetic ingredient (not through Superpower)
  Route: Topical serum/cream
• Compound: Argireline (acetyl hexapeptide-3)
  Mechanism for serums: Neurotransmitter-inhibitor — partial SNARE complex inhibition reducing expression-line-causing muscle contractions
  Evidence: RCT — single-site wrinkle-reduction effects vs. placebo (2013); original mechanistic characterization (2002)
  FDA status: Cosmetic ingredient; not evaluated or approved as a drug
  SP availability: Available as topical cosmetic ingredient (not through Superpower)
  Route: Topical serum
• Compound: GHK-Cu (copper tripeptide-1) — topical
  Mechanism for serums: Carrier peptide — delivers copper for collagen/elastin synthesis; modulates wound repair and antioxidant defense
  Evidence: In vitro collagen synthesis (established 1988); ex vivo GHK-Cu + HA synergy for collagen IV upregulation (2023); limited serum-specific RCT data
  FDA status: Cosmetic ingredient; not evaluated or approved as a drug
  SP availability: Available as topical cosmetic ingredient (not through Superpower)
  Route: Topical serum
• Compound: GEKG tetrapeptide (matrikine-derived)
  Mechanism for serums: Matrikine signal peptide — upregulates longevity genes; improves ECM architecture and dermal cell–matrix connections
  Evidence: In vitro and ex vivo evidence for ECM gene upregulation; nanoparticle delivery system shown to improve dermal delivery
  FDA status: Cosmetic ingredient
  SP availability: Available as topical cosmetic ingredient (not through Superpower)
  Route: Topical serum (including nanoparticle-enhanced formulations)
• Compound: GHK-Cu — injectable (compounded)
  Mechanism: Proposed systemic action based on preclinical and in vitro data; no controlled clinical trials establishing efficacy for any skin indication
  Evidence: Preclinical and in vitro only; no Phase 2/3 RCT for any indication
  FDA status: Not an FDA-approved drug — no formulation of GHK-Cu has been evaluated or approved by the FDA for any therapeutic indication. Availability through licensed 503A compounding pharmacies depends on the current FDA bulk drug substance nominations list; a licensed compounding pharmacy can confirm current eligibility in your state.
  SP availability: Superpower does not offer topical peptide serums or injectable compounded peptide aesthetic therapies. Superpower's biomarker testing includes relevant baseline markers (IGF-1, hs-CRP, CMP) for anyone considering injectable peptide therapy with a third-party provider.
  Route: Subcutaneous injection

Compounds listed as cosmetic ingredients are regulated under FDA cosmetics law and are not evaluated or approved to diagnose, treat, cure, or prevent any disease or medical condition.

Peptide Serum Ingredients: Individual Profiles

Peptide serum ingredients differ in mechanism, evidence level, and appropriate formulation context. The following profiles cover the most clinically supported ingredients found in peptide serums.

Palmitoyl pentapeptide (pal-KTTKS / Matrixyl): the most-studied signal peptide in serum contexts

Pal-KTTKS is the palmitoyl-modified form of the pentapeptide KTTKS, itself a matrikine fragment — a naturally occurring ECM-derived peptide that signals fibroblasts to produce new collagen. The palmitoyl fatty acid chain significantly increases lipophilicity, enabling passage through the stratum corneum lipid barrier. Farwick and colleagues, writing in Experimental Dermatology in 2011, demonstrated matrikine-triggered collagen induction in human dermal fibroblasts, validating the matrikine concept that peptide fragments of ECM precursors augment collagen production.

The clinical benchmark for this ingredient is a 12-week double-blind split-face RCT conducted by Robinson and colleagues and published in the International Journal of Cosmetic Science in 2005, which reported wrinkle count and fine line reduction at 3 ppm concentration. [RCT] The finding that effective concentrations are very low — 3 parts per million — has important implications for evaluating products: a serum can contain a cosmetically insignificant amount of pal-KTTKS and still list it on the label. Concentration disclosure is therefore the most important signal of whether clinical evidence is likely to apply to a specific product.

Choi and colleagues confirmed in a 2014 permeation study that pal-KTTKS penetrates all skin layers, validating that topical application of this modified peptide delivers the active compound to the fibroblast-containing tissue layer. [Permeation study]

Argireline (acetyl hexapeptide-3): serums for expression lines

Argireline is a synthetic analog of the N-terminal sequence of synaptosomal-associated protein of 25 kDa (SNAP-25), a core component of the SNARE complex that governs neurotransmitter vesicle release at the neuromuscular junction. By competing with the endogenous SNAP-25 sequence, argireline partially inhibits SNARE complex formation, reducing the acetylcholine release that triggers facial muscle contraction.

Blanes-Mira and colleagues published the original mechanistic characterization in the International Journal of Cosmetic Science in 2002, identifying argireline's SNARE-inhibiting mechanism and documenting wrinkle depth reduction in initial testing. [Mechanistic characterization] Wang and colleagues subsequently published a 2013 randomized placebo-controlled trial in the American Journal of Clinical Dermatology, reporting wrinkle-reduction effects versus placebo — the study reported a 48.9% figure on its wrinkle-appearance assessment scale, but the study was single-site, not a regulatory drug trial, and the result has not been independently replicated at scale. Cosmetic ingredient outcomes are not evaluated by the FDA as clinical efficacy endpoints. [RCT]

Argireline serums are most relevant for the periorbital and forehead areas where expression lines are primary. The effect is substantially milder than intramuscular botulinum toxin and reversible. It does not produce the paralytic effect of botulinum toxin — the mechanism is partial inhibition at physiological peptide concentrations, not irreversible enzyme cleavage.

GHK-Cu: the copper peptide in serums

GHK-Cu (glycine-histidine-lysine copper complex) is among the most biologically multifunctional peptides in common cosmetic serum use. As a carrier peptide, its primary role is delivering copper to the dermis, where copper is a required cofactor for lysyl oxidase — the enzyme that cross-links newly synthesized collagen and elastin chains into functional fibrils. Without adequate copper, lysyl oxidase activity is impaired, reducing the cross-linking that produces structurally competent collagen and elastin fibers.

Beyond copper delivery, Pickart and Margolina, in a comprehensive review published in the International Journal of Molecular Sciences in 2018, documented GHK-Cu regenerative actions including wound contraction promotion, antioxidant gene expression upregulation, anti-inflammatory signaling, and regulation of multiple biochemical pathways relevant to skin biology including DNA repair, wound-healing gene networks, and antioxidant defense. [Review]

For serum formulation, Jiang and colleagues demonstrated in 2023 in the Journal of Cosmetic Dermatology that GHK-Cu + HA collagen IV synergy occurs in fibroblast models and ex vivo skin. Ex vivo and in vitro findings do not always translate to measurable in-vivo cosmetic outcomes. [In vitro / ex vivo] In-vivo serum trials at matched concentrations have not been published; serums pairing GHK-Cu with HA represent a formulation strategy with preliminary scientific support.

Mortazavi and colleagues, in a 2025 review in BioImpacts, described penetration and stability constraints that topical peptide formulations face. Injectable GHK-Cu has not been studied in adequate and well-controlled clinical trials for any cosmetic skin indication and is not FDA-approved for any use. [Review]

Advanced delivery technologies in peptide serums

For peptides with limited passive penetration, several delivery enhancement technologies appear in premium serum formulations. Sommer and colleagues, in a 2018 study published in the European Journal of Pharmaceutical Sciences, evaluated colloidal carrier systems (nanoparticles and liposomes) for delivery of the GEKG tetrapeptide, finding that lipid nanoparticles improved dermal delivery compared to aqueous formulations. [In vitro / ex vivo]

Lim and colleagues, in 2018 in Scientific Reports, reviewed molecular modifications to enhance skin permeation of anti-wrinkle peptides, cataloguing D-amino acid substitution, cyclization, CPP conjugation and related strategies. These modifications can substantially improve bioavailability for peptides that would otherwise fail to penetrate. Their presence in a formulation — disclosed or not — directly affects whether the peptide evidence applies.

Regulatory Status at a Glance

As of April 2026, peptide serum ingredients carry the following regulatory statuses:

• Palmitoyl pentapeptide-4 (pal-KTTKS/Matrixyl): Cosmetic ingredient, FDA cosmetics law. No prescription required.
• Argireline (acetyl hexapeptide-3): Cosmetic ingredient, FDA cosmetics law. No prescription required.
• GHK-Cu (topical): Cosmetic ingredient, FDA cosmetics law. No prescription required.
• GEKG tetrapeptide: Cosmetic ingredient, FDA cosmetics law. No prescription required.
• GHK-Cu (injectable/compounded): Not an FDA-approved drug — no formulation of GHK-Cu has been evaluated or approved by the FDA for any therapeutic indication. Its availability through licensed 503A compounding pharmacies depends on the current FDA bulk drug substance nominations list; a licensed compounding pharmacy can confirm whether it can lawfully dispense GHK-Cu in your state at the time you request it. Requires prescription from a licensed healthcare provider. The compounding status of injectable GHK-Cu is separate from FDA bulk drug substance actions through 2026 concerning other peptides (including the April 22, 2026 PCAC recommendation against CJC-1295 and ipamorelin).

Considerations When Choosing a Peptide Serum

Choosing a peptide serum involves evaluating formulation quality, ingredient specificity, evidence applicability, and realistic expectations. This is a consumer decision, not a clinical prescription decision — but applying clinical evidence standards improves outcome probability.

Specific ingredient by INCI name: Trademarked blend names (for example, proprietary "complex" or "matrix" formulations) reference specific compounds but vary in what they contain. Always verify the INCI ingredient name on the label. The INCI name for pal-KTTKS is "palmitoyl pentapeptide-4." For argireline, it is "acetyl hexapeptide-3." For GHK-Cu, it is "copper tripeptide-1." If the INCI name is absent or buried, the concentration disclosure is likely also absent.

Concentration disclosure: The Robinson 2005 RCT for pal-KTTKS was conducted at 3 ppm. Pai, Bhandari, and Shukla's 2017 review established concentration as a primary determinant of cosmeceutical peptide bioactivity. A product that does not disclose concentration provides no basis for expecting the clinical evidence to apply. Concentration disclosure, while not legally mandated for cosmetics, is a quality signal.

Stability protection: Errante and colleagues' 2021 stability research demonstrated that cosmeceutical peptides are susceptible to protease degradation. A serum with a pH-buffered formulation, appropriate preservative system, and opaque or airless packaging is more likely to deliver stable peptide than a product without these features. Storage instructions matter — Ruiz and colleagues confirmed in 2007 that peptide stability in cosmetic formulations is significantly affected by storage conditions.

Injectable vs. topical framing: Topical peptide serums produce localized cosmetic-level effects at the skin surface. Injectable peptide compounds are a separate regulatory category; injectable GHK-Cu is not FDA-approved for any skin indication and has not been studied in adequate and well-controlled trials for cosmetic skin outcomes. Choice of a topical peptide serum is a cosmetic decision that is distinct from any consideration of injectable compounded products.

Comparative evidence caution: Direct comparisons between peptide serums and injectable peptides, between different serum formulations, or between peptides and retinoids require explicit caveats — different populations, different endpoints, different measurement timeframes. These compounds have not been studied head-to-head in adequately powered comparative trials.

Safety Considerations

Topical cosmetic peptide serums are generally well-tolerated. They are not typically associated with the irritation, photosensitization, or barrier disruption reported with retinoids, AHAs, or benzoyl peroxide, though individual reactions to any cosmetic ingredient remain possible. Most formulations are compatible with sensitive skin, though individual reactions to vehicle ingredients (fragrances, preservatives, emulsifiers) remain possible regardless of the peptide content.

Ledwoń, Errante, and colleagues' 2021 review of cosmeceutical peptides noted that the commercially significant peptide classes had not been associated with systemic toxicity at typical cosmetic application doses in the evidence available at that time. Leroux and colleagues, in a 2020 study in the International Journal of Cosmetic Science, noted that matrikine-derived peptides in serum formulations were associated with longevity genes and ECM architecture without evidence of proliferative or oncogenic signaling at cosmetic concentrations. [In vitro]

Herndon and colleagues, in a 2015 open-label trial of a multi-ingredient anti-aging moisturizer with palmitoyl peptides published in the Journal of Drugs in Dermatology, reported facial skin improvements without significant adverse effects across the study population. [Open-label clinical trial]

Broadly applicable considerations for topical peptide serum use:

• Fragrance-free formulations are preferable for sensitive skin or contact dermatitis history — reactions to vehicle ingredients are more common than reactions to the peptide actives
• Avoid high-concentration direct acid application immediately before or after peptide serums — acidic pH may degrade peptide stability on the skin surface
• Patch testing is appropriate for any new formulation before full-face application

For compound-specific safety information on injectable peptide approaches, see the individual compound pages.

What to Test Before Starting Injectable Peptide Therapy

Peptide serums require no laboratory monitoring. For anyone considering an injectable peptide approach — separate from topical serums — baseline biomarker testing establishes the reference points a provider needs to assess safety and monitor response.

• IGF-1: The primary downstream marker of GH axis activity. Testing IGF-1 levels before any injectable peptide with systemic GH-related effects establishes baseline axis function.
• Comprehensive metabolic panel (CMP): Covers liver enzymes (ALT, AST), kidney function (creatinine, eGFR), and electrolytes. Standard safety baseline for any injectable compound with hepatic or renal clearance.
• CBC: General hematologic safety baseline for injectable therapy.
• hs-CRP: Systemic inflammation marker. Baseline hs-CRP contextualizes any tissue remodeling response and identifies pre-existing inflammatory burden.
• Copper serum levels: If a provider is considering injectable GHK-Cu, they may evaluate your baseline copper status as part of their overall safety assessment, though there are no standardized monitoring requirements for this non-FDA-approved compounded product.

IGF-1, a comprehensive metabolic panel, and CBC provide the core baseline before any injectable peptide protocol. Establishing these values gives a provider the reference points needed to interpret any changes and confirm that organ function is appropriate for injectable use.

How to Access Injectable Peptide Approaches Safely

Peptide serums are over-the-counter cosmetic products requiring no prescription or clinical involvement. Injectable peptide therapy is a different category entirely. Injectable compounded peptides require evaluation by a licensed healthcare provider, a prescription, and follow-up monitoring.

Injectable GHK-Cu is a compounded, non-FDA-approved peptide with no approved indication. Decisions about whether to pursue any injectable compounded peptide are made by a licensed provider based on an individual's clinical profile and goals — not on topical-serum efficacy comparisons. A provider evaluation for injectable peptide approaches typically covers health history, current medications, baseline laboratory values, and an assessment of whether the specific compound's evidence level is appropriate for the individual's goals and health status. Access through a licensed provider and a state-licensed compounding pharmacy provides defined dosing, documented sourcing, and clinical oversight that unregulated online sources cannot provide. Licensed 503A compounding pharmacies operate under state board oversight and USP compounding standards, which differ from the cGMP manufacturing standards that apply to FDA-approved pharmaceutical products.

Ash and colleagues, in a 2024 systematic review of topical exosome and peptide therapies in Aesthetic Surgery Journal Open Forum, described peptide approaches for skin — noting that injectable peptides occupy a newer, less thoroughly studied tier than the topical cosmeceutical category with decades of formulation experience.

Understanding Your Baseline

Evaluating peptide serums effectively requires distinguishing between the evidence for an ingredient and the evidence for a specific product. The gap between a published RCT and a commercial formulation can be large. Concentration, vehicle, stability, and delivery enhancement determine whether any claimed peptide benefit applies to the product in hand.

For anyone considering moving beyond topical serums to injectable approaches, that evidence gap is wider still. Baseline biomarker data transforms that conversation from anecdote to science. That principle — test first, then decide — is central to Superpower's approach to preventive health. Whether the discussion with your provider leads to optimizing a topical serum approach or evaluating an injectable protocol, the starting point is the same: objective data about your current biology.

Important Notice — Topical Cosmetic Peptide Ingredients

Palmitoyl pentapeptide-4 (pal-KTTKS/Matrixyl), acetyl hexapeptide-3 (argireline), copper tripeptide-1 (GHK-Cu topical), GEKG tetrapeptide, and related peptide serum ingredients discussed in this article are cosmetic ingredients regulated under FDA cosmetics law. Cosmetic ingredients are not evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Claims about effects beyond cosmetic appearance are not supported by FDA evaluation. This page is provided for educational purposes only and does not constitute medical advice.

Important Safety Information — Injectable GHK-Cu (Compounded)

Compounded injectable GHK-Cu is not an FDA-approved drug — no formulation of GHK-Cu has been evaluated or approved by the FDA for any therapeutic indication. Compounding is a pharmacy practice, not an FDA approval. Its availability through licensed 503A compounding pharmacies depends on the current FDA bulk drug substance nominations list; a licensed compounding pharmacy can confirm whether it can lawfully dispense GHK-Cu in your state at the time you request it. The safety and efficacy of injectable GHK-Cu for any skin indication have not been established through adequate and well-controlled clinical trials. A prescription from a licensed healthcare provider is required. Because injectable GHK-Cu has not been studied in adequate and well-controlled clinical trials, a full safety profile — including populations who should not receive it — has not been established. Your prescribing provider will review your health history and identify any individual factors that would make injectable GHK-Cu inappropriate for you. The compounding status of injectable GHK-Cu is separate from the FDA bulk drug substance actions announced in early 2026 regarding certain other peptides; compounding eligibility for any specific peptide can change as the FDA updates its 503A bulks list, and your prescribing provider or compounding pharmacy is the authoritative source for current availability. Because injectable GHK-Cu is not an FDA-approved drug, there is no FDA-approved package insert for it; prescribing information is provided by your licensed healthcare provider and the dispensing compounding pharmacy.

Disclaimer: This article discusses topical cosmetic peptide serum ingredients and the injectable form of GHK-Cu. Topical cosmetic peptides are regulated as cosmetic ingredients and are not evaluated or approved to diagnose, treat, cure, or prevent any disease. Injectable GHK-Cu is not FDA-approved and requires a prescription. Superpower does not offer topical peptide serums.